News Eli Lilly makes $7.8bn takeover play for Centessa Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.
News Eisai joins with Pokémon for sleep awareness drive Eisai has launched a campaign to raise awareness of sleep disorders in Japan, via a partnership with smartphone app Pokémon Sleep.
News FDA turns down Hetlioz for jet lag once again Vanda will continue to push for approval of Hetlioz for jet lag, despite the FDA saying its trial designs were not satisfactory.
News Lundbeck bows out of bidding war for Avadel Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.
News Lundbeck makes bid for Avadel, trying to displace Alkermes Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.
News Alkermes breaks new ground in narcolepsy with orexin drug Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
